UBS Group
CRDF icon

UBS Group’s Cardiff Oncology CRDF Stock Holding History

UBS Group’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$649K Buy
400,576
+313,147
+358% +$643K ﹤0.01% 5884
2025
Q4 		$246K Sell
87,429
-118,746
-58% -$276K ﹤0.01% 6468
2025
Q3 		$425K Buy
206,175
+8,737
+4% +$24.1K ﹤0.01% 6213
2025
Q2 		$622K Buy
197,438
+110,903
+128% +$338K ﹤0.01% 5838
2025
Q1 		$272K Sell
86,535
-196,817
-69% -$778K ﹤0.01% 6326
2024
Q4 		$1.23M Buy
283,352
+234,788
+483% +$734K ﹤0.01% 5148
2024
Q3 		$130K Buy
48,564
+6,599
+16% +$15.6K ﹤0.01% 6172
2024
Q2 		$93.2K Buy
41,965
+39,003
+1,317% +$147K ﹤0.01% 6208
2024
Q1 		$15.8K Sell
2,962
-393
-12% -$1.04K ﹤0.01% 7027
2023
Q4 		$4.96K Buy
3,355
+3,292
+5,225% +$3.98K ﹤0.01% 7810
2023
Q3 		$88 Sell
63
-3,751
-98% -$6.33K ﹤0.01% 8913
2023
Q2 		$5.61K Sell
3,814
-11,876
-76% -$19.2K ﹤0.01% 7435
2023
Q1 		$25.9K Buy
15,690
+10,005
+176% +$17.2K ﹤0.01% 6895
2022
Q4 		$7.96K Sell
5,685
-2,760
-33% -$3.95K ﹤0.01% 8838
2022
Q3 		$13K Buy
8,445
+8,403
+20,007% +$20.2K ﹤0.01% 8014
2022
Q2 		$0 Sell
42
-6,942
-99% -$11.6K ﹤0.01% 10390
2022
Q1 		$17K Sell
6,984
-5,080
-42% -$18K ﹤0.01% 7639
2021
Q4 		$72K Buy
12,064
+8,704
+259% +$51.9K ﹤0.01% 6588
2021
Q3 		$22K Buy
+3,360
New +$21.1K ﹤0.01% 7053
2021
Q1 		– Sell
-634
Closed -$11K – 9046
2020
Q4 		$11K Sell
634
-3,145
-83% -$55.3K ﹤0.01% 7399
2020
Q3 		$53K Sell
3,779
-743
-16% -$4.91K ﹤0.01% 5599
2020
Q2 		$23K Sell
4,522
-5,088
-53% -$10.4K ﹤0.01% 6457
2020
Q1 		$9K Buy
9,610
+7,213
+301% +$10.2K ﹤0.01% 6981
2019
Q4 		$3K Sell
2,397
-5,310
-69% -$7.57K ﹤0.01% 7737
2019
Q3 		$12K Buy
7,707
+2,939
+62% +$5.72K ﹤0.01% 7045
2019
Q2 		$12K Buy
4,768
+3,974
+501% +$12.7K ﹤0.01% 6939
2019
Q1 		$3K Sell
794
-5,825
-88% -$20.8K ﹤0.01% 7327
2018
Q4 		$21K Buy
6,619
+3,593
+119% +$16.4K ﹤0.01% 6744
2018
Q3 		$15K Buy
3,026
+620
+26% +$2.94K ﹤0.01% 6957
2018
Q2 		$11K Buy
2,406
+2,100
+686% +$35.1K ﹤0.01% 7069
2018
Q1 		$8K Buy
306
+116
+61% +$2.86K ﹤0.01% 6996
2017
Q4 		$4K Sell
190
-261
-58% -$11.6K ﹤0.01% 7457
2017
Q3 		$24K Buy
451
+293
+185% +$18.3K ﹤0.01% 6319
2017
Q2 		$14K Sell
158
-34
-18% -$2.19K ﹤0.01% 6535
2017
Q1 		$16K Sell
192
-275
-59% -$37.3K ﹤0.01% 6304
2016
Q4 		$71K Buy
467
+326
+231% +$76.1K ﹤0.01% 5552
2016
Q3 		$46K Sell
141
-20
-12% -$7.29K ﹤0.01% 5585
2016
Q2 		$53K Buy
161
+45
+39% +$15.5K ﹤0.01% 5475
2016
Q1 		$39K Buy
116
+11
+10% +$3.74K ﹤0.01% 5680
2015
Q4 		$41K Buy
105
+29
+38% +$11.4K ﹤0.01% 5996
2015
Q3 		$31K Buy
76
+5
+7% +$2.62K ﹤0.01% 6249
2015
Q2 		$52K Sell
71
-471
-87% -$334K ﹤0.01% 5980
2015
Q1 		$266K Buy
542
+315
+139% +$134K ﹤0.01% 4653
2014
Q4 		$71K Buy
+227
New +$73.5K ﹤0.01% 6051

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return

UBS Group's CRDF Position: Q1 2026 in Review

UBS Group increased its Cardiff Oncology (CRDF) stake by 358% in Q1 2026, buying an estimated $643K and bringing the position to 400,576 shares worth $649K. The position accounts for ﹤0.01% of the portfolio, ranked #5884.

UBS Group first reported a position in CRDF in Q4 2014 and has held it in 44 quarters since. The position peaked at $1.23M in Q4 2024. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2026.

  • UBS Group held 400,576 shares of Cardiff Oncology worth $649K as of Q1 2026.
  • UBS Group bought 313,147 Cardiff Oncology shares in Q1 2026, an estimated $643K.
  • Cardiff Oncology made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5884 holding.
  • UBS Group first reported a position in Cardiff Oncology in Q4 2014 and has held it in 44 quarters since.
  • UBS Group's Cardiff Oncology position peaked at $1.23M in Q4 2024.
  • 116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.